Most kidney cancers are found by accident. Clear cell renal cell carcinoma (ccRCC) makes up roughly 80 percent of renal malignancy, yet has no approved liquid biopsy, so diagnosis waits on an abdominal scan ordered for something else. A urinary multi-omics study in EMBO Molecular Medicine went after that gap, running proteomics, lipidomics, and untargeted metabolomics on the same urine from 22 ccRCC patients, 9 with non-clear-cell tumors, and 12 matched controls, then distill

Advanced mycosis fungoides and Sezary syndrome get treated from a rotating menu of retinoids, interferon, methotrexate, chemotherapy and newer targeted agents, and no molecular test says who belongs on which arm. Tissue proteomics offers one way in. A group at Peking Union Medical College Hospital profiled 33 lesional biopsies from 31 patients with advanced cutaneous T-cell lymphoma (CTCL), pairing DIA mass spectrometry on laser-microdissected tumor regions with RNA-seq on a

Confirming endometriosis still usually means laparoscopy, and most patients wait years to get it. A multi-omics study in Frontiers in Endocrinology (August 2026) asked how much of that signal survives in a plain blood draw. Wenwei Pan and colleagues profiled serum from 88 women (44 with endometriosis, 22 with benign ovarian cysts, 22 healthy controls), pairing the Olink Target 96 Inflammation panel with untargeted metabolomics on a UHPLC-Q Exactive Orbitrap. The metabolites c

Pyrotinib clears HER2-positive breast tumours in a good share of patients, and nothing in the pre-treatment workup says which share a given patient falls into. A group at the Fourth Hospital of Hebei Medical University went after that gap with tumour proteomics, profiling pre-therapy biopsies from six women who later reached a pathological complete response (pCR) and six who did not. The 617 proteins separating those groups were pushed through co-expression networks, 127 mach

Asparaginase cures leukemia, and it sometimes inflames the pancreas on the way. Between 5% and 20% of children treated for acute lymphoblastic leukemia (ALL) develop asparaginase-associated pancreatitis, and no validated test says in advance who is at risk. A JCI Insight study ran lipidomics and proteomics on banked blood from 161 pediatric ALL patients in two Dana-Farber trial cohorts, sampled before any asparaginase dose and again at the end of induction. What separated the